SCHEMBL3703

SCHEMBL3703

N[C@@H](CCCCNC(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 3/20 0.69
DPP7 Q9UHL4 3/20 0.69
ANPEP P15144 1/20 0.67
DPP4 P27487 2/20 0.64
DPP9 Q86TI2 2/20 0.64
HTT P42858 1/20 0.62
SLC1A3 P43003 1/20 0.62
SLC1A1 P43005 1/20 0.62
FOLH1 Q04609 3/20 0.59
TGM2 P21980 1/20 0.59
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
KEAP1 Q14145 2/20 0.56
NFE2L2 Q16236 2/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704 1.00 DPP8 (0.69) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL10962932 1.00 DPP8 (0.69) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL20570522 0.99 DPP8 (0.68) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL20570366 0.99 DPP8 (0.68) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL9317271 0.99 DPP8 (0.68) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL9656664 0.96 DPP8 (0.64) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL31134030 0.93 DPP8 (0.68) DPP8DPP7ANPEPDPP4DPP9
Phenylalanine SCHEMBL10348899 0.93 DPP8 (0.62) DPP8DPP7ANPEPDPP4DPP9
Trifluoroacetic Acid SCHEMBL30788185 0.93 DPP8 (0.62) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL23542526 0.92 DPP8 (0.64) DPP8DPP7ANPEPDPP4DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118126117-A Synthesis method of copper peptide 深圳市维琪科技股份有限公司 2024-06-04 CN disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
WO-2021256546-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS 味の素株式会社 2021-12-23 WO disclosed
EP-1921062-A2 Amino acid derivatives as HIV aspartyl protease inhibitors Ambrilia Biopharma Inc. (CA) 2008-05-14 EP disclosed
EP-1263716-B1 AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS AMBRILIA BIOPHARMA INC (CA) 2008-01-02 EP disclosed
US-20060079550-A1 Amino acid derivatives useful for the treatment of alzheimer's disease ELAN PHARMACEUTICALS, INC. 2006-04-13 US disclosed
EP-1458378-A1 AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-09-22 EP disclosed
WO-2003045378-A1 AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-06-05 WO disclosed
EP-1263716-A2 AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS Pharmacor Inc. (CA) 2002-12-11 EP disclosed
EP-0239062-B1 N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-05-29 EP disclosed
US-4916119-A IMMUNOSTIMULANT TRIPEPTIDES RHONE-POULENC INDUSTRIES (FR) 1990-04-10 US disclosed
US-4742048-A Tetrapeptides and pentapeptides, their preparation and compositions containing them RHONE-POULENC INDUSTRIES (FR) 1988-05-03 US disclosed
US-4741900-A Antibody-metal ion complexes CYTOGEN CORPORATION (US) 1988-05-03 US disclosed
EP-0109020-B1 DERIVATIVES FROM TRICYCLIC AMINO ACIDS, PROCESS FOR THEIR PREPARATION, COMPOUNDS CONTAINING THEM AND THEIR USE, AS WELL AS BICYCLIC AMINO ACIDS AS INTERMEDIATES AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1987-09-23 EP disclosed
EP-0150263-A1 Derivatives of cis, endo-2-azabicyclo-[3.3.0]-octane-3-carboxylic acid, process for their preparation, medicaments containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1985-08-07 EP disclosed
US-4511719-A Nα-(3-Cyanopropanoyl)-aminocarboxylic acid derivatives and their use DEGUSSA AKTIENGESELLSCHAFT (DE) 1985-04-16 US disclosed
EP-0111873-A1 Derivatives of cis, endo-2-azabicyclo-(5.3.0)-decane-3-carboxylic acid, process for their preparation, compositions containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1984-06-27 EP disclosed
EP-0109020-A2 Derivatives from tricyclic amino acids, process for their preparation, compounds containing them and their use, as well as bicyclic amino acids as intermediates and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-23 EP disclosed
US-4426532-A CHEMICAL INTEREDIATES DEGUSSA AG (DE) 1984-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079550-A1 Amino acid derivatives useful for the treatment of alzheimer's disease BACE1, APP, PSEN1 DPP8 773/4885DPP7 373/4885ANPEP 8/4885
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS DAO, ALAD, BCAT1 DPP8 1787/4885DPP7 2381/4885ANPEP 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.